**Health technology assessment in osteoporosis**

Mickael Hiligsmann, PhD,1,2 John A. Kanis, MD,3 Juliet Compston, MD,4 Cyrus Cooper, MA, DM,5 Bruno Flamion, MD, PhD,6 Pierre Bergmann, MD, PhD,7 Jean-Jacques Body, MD, PhD,8 Steven Boonen, MD, PhD,9 Olivier Bruyere, PhD,2 Jean-Pierre Devogelaer, MD,10 Stefan Goemaere, MD,11 Jean-Marc Kaufman, MD, PhD,12 Serge Rozenberg, MD,13 Jean-Yves Reginster, MD, PhD2

**Affiliations**

1. Department of Health Service Research, School for Public Health and Primary Care (CAPHRI), Maastricht University, The Netherlands
2. Department of Public Health, Epidemiology and Health Economics, University of Liège, Belgium

3. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK

4. Department of Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

5. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

6. Physiology and Pharmacology Department, University of Namur, Namur, Belgium

7. Department of Radioisotopes, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium

8. Department of Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium

9. Center for Metabolic Bone Diseases, Katholieke University Leuven, Leuven, Belgium

10. Department of Rheumatology, Saint Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium

11. Department of Rheumatology and Endocrinology, Ghent University Hospital, Gent, Belgium

12. Department of Endocrinology, Ghent University Hospital, Gent, Belgium

13. Department of Gynaecology–Obstetrics, CHU ST Pierre, Université Libre de Bruxelles, Brussels, Belgium

*Corresponding author:* Mickael Hiligsmann, Department of Health Service Research, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands
Tel +31 43 38 82 219 Fax +31 43 38 841 62. Email: m.hiligsmann@maastrichtuniversity.nl

This paper is based on an expert consensus meeting held by the Belgian Bone Club under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).

**Abstract**

We review the various aspects of health technology assessment in osteoporosis, including epidemiology and burden of disease, and assessment of the cost-effectiveness of recent advances in the treatment of osteoporosis and the prevention of fracture, in the context of the allocation of healthcare resources by decision-makers in osteoporosis. This article was prepared on the basis of a symposium held by the Belgian Bone Club and the discussions surrounding that meeting, and is based on a review and critical appraisal of the literature. Epidemiological studies confirm the immense burden of osteoporotic fractures for patients and society with lifetime risks of any fracture of the hip, spine and forearm of around 40% for women and 13% for men. The economic impact is also large, for example, Europe's six largest countries spent €31 billion on osteoporotic fractures in 2010. Moreover, the burden is expected to increase in the future with demographic changes and increasing life expectancy. Recent advances in the management of osteoporosis include novel treatments, better fracture risk assessment notably via fracture risk algorithms, and improved adherence to medication. Economic evaluation can inform decision-makers in healthcare on the cost-effectiveness of the various interventions. Cost-effectiveness analyses suggest that the recent advances in the prevention and treatment of osteoporosis may constitute an efficient basis for the allocation of scarce healthcare resources. In summary, health technology assessment is increasingly used in the field of osteoporosis and could be very useful to help decision-makers efficiently allocate healthcare resources.

**Keywords:** Burden of disease; cost-effectiveness; economic evaluation; health technology assessment; osteoporosis

**Introduction**

Osteoporosis is a major cause of fracture worldwide, most notably of the hip, spine, and forearm. Osteoporotic fracture is strongly associated with morbidity, especially in terms of pain and disability. Hip and vertebral fractures are also associated with high mortality in the 2 years after the event [[1](#_ENREF_1), [2](#_ENREF_2" \o "Kanis, 2004 #466)]. Osteoporosis is a common disease and is associated with a substantial healthcare burden. In western countries, one in two women and one in five men over the age of 50 years will experience an osteoporotic fracture during their remaining lifetime [[3](#_ENREF_3), [4](#_ENREF_4)]. Heterogeneity in hip fracture risk is observed around the world [[5](#_ENREF_5)], with estimates of a lifetime risk at the age of 50 years that vary from 1% in women from Turkey to 28.5% in women from Sweden [[6](#_ENREF_6)]. The worldwide direct and indirect annual costs of hip fracture in 1990 were estimated at US$35 billion, with further increases predicted over the next 50 years [[7](#_ENREF_7)]. In six major European countries, the burden of osteoporotic fractures was estimated in 2010 at €31 billion [[8](#_ENREF_8)]. Fortunately, there is currently an array of diagnostic tools and effective treatments available for the management of osteoporosis [[9](#_ENREF_9)].

Considering the limited healthcare resources available, alongside major recent innovations in the management of osteoporosis, it is becoming increasingly important to allocate healthcare resources appropriately and efficiently. Health technology assessment (HTA) aims to evaluate the clinical, economic, social, and ethical implications of the prevention and treatment of a condition—in this case osteoporotic fracture—to guide national healthcare policies (for example, reimbursement decisions). The principal aim of HTA is to form a bridge between scientific experts in clinical practice and decision-makers in healthcare, in order to make the most appropriate use of available strategies for prevention and management. The ultimate target is evidence-based prioritization of national needs for healthcare technology—be it for the prevention of fracture itself or management post-fracture—for optimization of public health initiatives. It was against this background that the Belgian Bone Club held a symposium to explore the issue from the clinician's point of view. This paper was prepared on the basis of the presentations and discussions surrounding that meeting, as well as review and critical appraisal of the literature. Our aim was to discuss the various aspects of HTA in osteoporosis, including epidemiology and estimation of the burden of disease, and assessment of the cost-effectiveness of the recent advances in the management of osteoporosis.

**Health technology assessment**

According to the International Network of Agencies for Health Technology Assessment [[10](#_ENREF_10)], HTA is the systematic evaluation of “the medical, social, ethical and economic implications of development, diffusion, and use of health technology.” Its purpose is to support healthcare decisions and inform policy-making through objective information at local, national, or international levels. The aim of HTA is to improve the quality of care by promoting an appropriate and rational use of healthcare technologies [[11](#_ENREF_11)] and by facilitating the introduction and dissemination of new technologies.

Health technology includes not only drugs, medical equipment, and devices, but also prevention, diagnostic, and treatment procedures. HTA is conducted by interdisciplinary groups that use explicit analytical frameworks and draw from a variety of methods [[10](#_ENREF_10)]. This field of research was developed in the 1970s and 1980s in the USA and Europe, and has spread to the rest of the world over the last two decades [[12](#_ENREF_12)]. HTA government agencies are now operating in many countries. They have been established to provide advice to governments and address, at the national level, the containment of healthcare costs and the assessment of the impact of new technologies [[13](#_ENREF_13)]. The organization of HTA and its influence on the public policy-making process can vary markedly between countries [[14](#_ENREF_14)]. In addition, many research institutions are concerned with HTA [[15](#_ENREF_15)], for example, the National Health Service Centre for Reviews and Dissemination in the UK. In 2012, the International Network of Agencies for Health Technology Assessment consisted of 53 members from 29 countries [[10](#_ENREF_10)].

HTA is increasingly used by regulatory agencies to authorize a drug, device, or technology for market or reimbursement. HTA can be used to support decision-making by clinicians and patients. It may also be used by other bodies, for example, associations of health professionals, hospitals (for acquisition of new technologies), and companies (to aid product development and marketing decisions) [[16](#_ENREF_16)].

**Epidemiology and burden of osteoporosis**

The first step of HTA is to assess the epidemiology and burden of the disease or outcome concerned. Epidemiological studies performed in the early 1990s in white North American individuals aged over 50 years indicated that the lifetime risk for any fracture of the hip, spine, or forearm was 40% in women and 13% in men [[17](#_ENREF_17)]. Similar rates of fracture were reported in a study performed 10 years later in the UK General Practice Research Database (GPRD), with values of 53% for women and 21% for men [[18](#_ENREF_18)]. These data include fractures not linked to osteoporosis, such as those of the skull, hands or fingers, and ankles or toes. Lifetime risk for fracture of the hip, spine, and wrist has been estimated as 14%, 28%, and 13%, respectively, for women in the UK, and 3%, 6%, and 2% for their male counterparts [[7](#_ENREF_7)]. The risk of fracture rises progressively from the age of 50 years, and there is a substantial female excess at all-time points above that age.

Fracture rates are known to vary considerably according to geographical location [[5](#_ENREF_5)], which also influences HTA. Age-standardized incidences of hip fractures are currently available in 63 countries [[5](#_ENREF_5)]. The age-standardized incidence of hip fracture in Europe and North America is generally higher than in Asia and Africa, and there is also a large difference within Europe (763 per 100 000 women in Norway versus 418 per 100 000 women in England) [[19](#_ENREF_19)]. These differences correlate weakly with latitude [[20](#_ENREF_20)], activity [[21](#_ENREF_21)], and fall risk [[19](#_ENREF_19), [22](#_ENREF_22" \o "Roy, 2002 #461)], but not with bone mineral density (BMD). Geographical differences may be partly explained by time trends. Age, period, and birth cohort all impact on secular trends in hip fracture [[23](#_ENREF_23), [24](#_ENREF_24)], suggesting that there are determinants that operate throughout life; for example, even maternal vitamin D status may play a role [[25](#_ENREF_25)].

Data are available regarding incident trends in hip fracture from around 1928 up to the present. Steep and statistically significant increases in age-adjusted rates among men and women were observed in the middle to late 20th century. However, whilst global projections for hip fracture in the 1990s suggested sustained increases due to demographic changes in populations [[26](#_ENREF_26)], there is evidence that the trends in incidence are reaching a plateau, or may even have declined. This trend is most consistent in the USA, where hip fracture rates and subsequent mortality are declining (though with coincident increase in morbidities associated with hip fracture) [[27](#_ENREF_27)]. There is also evidence for similar trends in Europe and Oceania, but not (for the time being) in Asia [[28](#_ENREF_28), [29](#_ENREF_29" \o "Melton, 2009 #67)]. In Belgium, the age-standardized incidence of hip fracture fell from 5.60 per 1000 women aged over 50 years in 2000, to 5.22 per 1000 in 2007 [[30](#_ENREF_30)]. These data (excluding readmissions) also highlight a reversal of the secular trend for hip fracture in Belgian women, with a 1.1% reduction in the average yearly change in the incidence of hip fractures in the period 2000 to 2007 [[30](#_ENREF_30)], compared with a 2.1% increase reported between 1984 and 1996 [[31](#_ENREF_31)]. The reasons for this reversal are not entirely clear, though it could be linked to changes in risk factors [[28](#_ENREF_28)], most notably those acting in later life; for example, changes in patterns of physical activity, vitamin D insufficiency, and increasing survival of the frailest elderly were likely to contribute to the rise in hip fracture incidence in the second half of the century. On the other hand, reduction in rates of hip fracture in the last two decades may be linked to wider use of osteoporosis treatments—and some studies have revealed the recent decrease in hip fracture incidence coincided with increased use of osteoporosis treatments [[27](#_ENREF_27), [30](#_ENREF_30), [32](#_ENREF_32)]—as well as other possible factors, such as increased rates of obesity or improvements in nutrition or tobacco consumption. However, there is no single explanation, and no causal relationship can be ascertained between the increase in the use of osteoporosis medications and the decrease in hip fracture incidence [[30](#_ENREF_30), [33](#_ENREF_33" \o "Melton, 2005 #462)]. Further research is necessary to explore these trends in more depth. Despite a reduction in age-adjusted incidence in many countries, the absolute number of fractures is still increasing due to the aging of the population and increasing life expectancies. In Belgium, for example, the absolute number of hip fractures increased by 9% between 2000 and 2007 [[30](#_ENREF_30)].

A report launched by the International Osteoporosis Foundation (IOF) in collaboration with the European Federation of Pharmaceutical Industry Associations (EFPIA) has revealed the immense burden of osteoporotic fracture [[8](#_ENREF_8)]. For the year 2010, approximately 2.5 million new fractures occurred in Europe's five largest countries (France, Germany, Italy, Spain, UK) and Sweden alone [[8](#_ENREF_8)]. The economic impact of these fractures was estimated to be nearly €31 billion in that year [[8](#_ENREF_8)]. Approximately 34 000 deaths were causally related to these fractures and the burden expressed in quality-adjusted life years (QALYs) was estimated at 850 000 QALYs. Considering current trends in demography, the burden of osteoporosis is expected to further increase in the near future. The projected number of fractures in these major countries is 3.2 million by 2025, an increase of 29% [[8](#_ENREF_8)].

**Recent advances in the treatment of osteoporosis**

The diagnosis and treatment of osteoporosis is rapidly evolving. A variety of new treatments for osteoporosis has become available over the past few years [[34](#_ENREF_34)]. Fracture risk assessment is increasingly used to guide treatment decisions [[35](#_ENREF_35)], and the impact of non-adherence with osteoporosis medications on treatment efficacy has led to the development of behavioural interventions to improve adherence [[36](#_ENREF_36), [37](#_ENREF_37" \o "Landfeldt, 2011 #82)]. The assessment of these major advances from a clinician’s point of view is provided below, while the economic assessment will be discussed later.

*Novel treatment strategies*

Over recent years, new treatment strategies have become available to prevent and treat osteoporosis, including bazedoxifene [[38](#_ENREF_38)], denosumab [[39](#_ENREF_39)], ibandronate [[40](#_ENREF_40)], strontium ranelate [[41](#_ENREF_41)], and zoledronic acid [[42](#_ENREF_42)]. Other promising drugs are currently in development, such as odanacatib (a specific inhibitor of the osteoclast protease cathepsin K) and antibodies against the sclerostin and dickkopf-1 proteins [[34](#_ENREF_34)]. Systematic review of the clinical efficacy, effectiveness, and side effect profiles of these drugs is a crucial part of HTA. Good-quality systematic reviews of the evidence for the efficacy and safety of these drugs are available [9, [34](#_ENREF_34" \o "Rachner, 2011 #74), [43-46](#_ENREF_43)], and will not be discussed further here.

*Fracture risk assessment*

Evaluation of risk and prediction of outcome is another important component of HTA. It is well established that BMD is inversely related to fracture risk [[47](#_ENREF_47)]. For every 1.0 SD decrease in BMD at the hip, spine, or radius, there is an approximately 1.5- to 2-fold increase in fracture risk at any site. Measurement of BMD is therefore an integral part of the prediction of fracture risk. However, there are a host of other clinical risk factors that can improve fracture risk prediction, notably because they increase fracture risk in a manner that is at least partially independent of BMD. Examples are a prior history of fragility fracture, a parental history of hip fracture, current smoking, high alcohol intake, systemic glucocorticoids, and the presence of rheumatoid arthritis [[48](#_ENREF_48)]. Fracture risk prediction algorithms have been generated to combine results of BMD assessment with the presence of clinical risk factors, thereby improving the prediction of osteoporotic fracture.

Current fracture risk algorithms generally produce estimates of 10-year risk of fracture. The most widely used is the World Health Organization (WHO) fracture risk assessment tool, FRAX®, which is recommended by guidelines in North America, Europe, and Japan. The FRAX algorithm was developed using international population-based data for men and women aged 40 to 90 years. FRAX combines 11 parameters of risk (femoral neck BMD, age, sex, body mass index, prior fracture, parental history of hip fracture, rheumatoid arthritis, glucocorticoids, smoking, alcohol, and secondary osteoporosis) to calculate a 10-year probability for major osteoporotic fracture and for hip fracture [[35](#_ENREF_35)]. Other fracture risk prediction algorithms have also been produced which are not based on probability (i.e. do not incorporate the death risk), and are less widely used [[49-51](#_ENREF_49)]. A simpler score, produced by Ensrud et al, used a USA-based population of women aged 65 years or older to determine a 10-year risk of major osteoporotic or hip fracture using the risk factors of age and previous fractures with and without BMD. They considered that this simpler model may predict risk as well as the more complex FRAX algorithm [[49](#_ENREF_49)], but this is the subject of some debate [[52](#_ENREF_52)]. The Garvan Fracture Risk Calculator includes BMD, age, sex, previous fracture, and falls to produce 5- and 10-year risks of any fracture in men and women aged over 60 years [[51](#_ENREF_51)]. Finally, the Qfracture algorithm employs multiple risk factors, including comorbidities, medications, and falls, but not a prior fracture or BMD, to estimate 2-, 5-, and 10-year risks of hip, wrist, and vertebral fracture [[50](#_ENREF_50)].

The FRAX algorithm is the most widely used tool, and has been endorsed by international guidelines. However, it does have a number of limitations; for example, it only allows for inclusion of femoral neck BMD, but not BMD values at other sites. Moreover, FRAX does not incorporate the notion of dose-response for some of the risk factors, for example, previous fracture and glucocorticoids [[53](#_ENREF_53)]. Simple guidance for the adjustment of fracture probabilities on the basis of exposure to glucocorticoids and information on lumbar BMD are available [[54](#_ENREF_54), [55](#_ENREF_55" \o "Kanis, 2011 #135)]. FRAX, like all the models except QFracture (which ignores all previous fracture), may also underestimate risk if previous vertebral fractures are not accounted for, despite established evidence for the influence of incident fracture. Moreover, it does not formally take into account the number of previous fractures. The recent observational cohort study GLOW (Global Longitudinal Study of Osteoporosis in Women) collected information on 50 000 women in 10 countries [[56](#_ENREF_56)]. Compared with women with no previous fracture, the hazard ratio for incident fracture was 1.81 (95% confidence interval [CI], 1.66–1.97) in patients with one prior fracture, 2.98 (95% CI, 2.63–3.38) with two prior fractures, and 4.80 (95% CI, 4.11–5.60) with three prior fractures [[56](#_ENREF_56)]. Similarly, the presence of undiagnosed vertebral fracture was associated with a substantially increased risk for hip and new vertebral fracture [[57](#_ENREF_57)], but could only be incorporated in risk prediction algorithms by systematic evaluation of spinal radiographs. Clearly, this is not feasible for all consultations, though possible indications for vertebral imaging in fracture assessment should include low BMD, height loss, kyphosis, pain suggestive of a vertebral fracture, previous non-vertebral fracture, and reduced rib-to-pelvis distance. One potential drawback to FRAX may be that it does not include falls, which clearly contribute to the occurrence of fracture and are included in other risk tools [[50](#_ENREF_50), [51](#_ENREF_51" \o "Nguyen, 2007 #128)]. Although there is some evidence that including falls into FRAX would improve fracture risk prediction [[58](#_ENREF_58)], the incorporation of falls into FRAX may be problematic for a number of reasons discussed elsewhere [[53](#_ENREF_53)].

In conclusion, FRAX and other fracture risk algorithms enable fracture prediction based on clinical risk factors with or without BMD and provide a basis for setting intervention thresholds. Current strategies for external validation and comparisons of fracture risk algorithms involve procedures of discrimination, calibration, classification, and decision curve analysis, all of which have drawbacks and require further study [[52](#_ENREF_52)].

*Adherence to treatment*

The problem of medication non-adherence has emerged as a critical hurdle to osteoporosis management. Adherence with osteoporosis medications is poor and suboptimal [[59-61](#_ENREF_59)]. Several studies have suggested that between 50% and 75% of women who initiate oral bisphosphonate therapy are non-adherent within 1 year. Poor adherence reduces the effectiveness of osteoporosis treatment, resulting in lower BMD gains and subsequently higher fractures rates [[62](#_ENREF_62), [63](#_ENREF_63" \o "Ross, 2011 #160)]. Approximately 50% of the potential clinical benefits of oral bisphosphonates are lost due to non-adherence [[36](#_ENREF_36), [37](#_ENREF_37), [64](#_ENREF_64)] and the costs per QALY from these medications are doubled when assuming non-adherence [[64](#_ENREF_64)]. Non-persistence is the leading problem with adherence, with more than 90% of the clinical and economic burden of poor adherence resulting from non-persistence [[64](#_ENREF_64)].

Over the past few years, behavioural interventions and treatments with longer intervals between doses have been developed in order to improve medication adherence. Systematic reviews of these interventions identified a limited number of studies of variable quality suggesting that some intervention techniques may help improve medication adherence, but this requires further investigation [[65](#_ENREF_65), [66](#_ENREF_66)]. Different dosing regimens [[67](#_ENREF_67)], the use of a decision aid [[68](#_ENREF_68)], and education programs [[69](#_ENREF_69)] may also improve medication adherence.

**Economic evaluation**

Economic evaluation is as important a branch of HTA as the epidemiological and treatment aspects. The aim of economic evaluation is to examine outcomes and costs of healthcare interventions; it could be defined as the comparative analysis of two or more healthcare interventions in terms of both costs and impact on outcomes [[70](#_ENREF_70)]. By informing decision-makers about the relative cost-effectiveness of different healthcare interventions, economic evaluation can help decision-makers make rational decisions and efficiently allocate resources. Cost-effectiveness is currently considered to be the fourth hurdle in drug development, behind quality, safety, and efficacy [[71](#_ENREF_71)]. Although the most common application of economic evaluation is drug pricing and reimbursement [[72](#_ENREF_72)], the implementation and viability of any other health intervention (such as screening or information campaigns) also depend on their evaluation and their relative cost-effectiveness.

With the rising demand for healthcare, budget constraints, and the rapid development of health technologies, economic evaluation plays an increasingly large role in the decision-making process for healthcare interventions. This has led to an increase in the number of published economic evaluations in the literature and to an increased use of economic data in the healthcare decision-making process (in particular, for drug reimbursement). Many countries currently require economic evaluation as part of the reimbursement process for drugs [[73](#_ENREF_73)].

The four main types of economic evaluation all approach costs in the same way, but differ in the way they approach outcomes [[70](#_ENREF_70)]:

* *Cost-minimization analysis* is used where the consequences of two or more interventions are broadly equivalent, and so the difference between them is limited to a cost comparison. This approach is only meaningful for agents with similar efficacies or side effects, which is difficult to apply to a heterogeneous class like the osteoporosis drugs [[74](#_ENREF_74)].
* *Cost-benefit analysis* measures both costs and benefits in monetary terms. This approach aims to demonstrate that a program will yield to a net welfare gain, and ranks interventions according to the net benefit they provide. The practical difficulties of measurement and valuing health benefits have limited the use of this type of analysis in healthcare [[75](#_ENREF_75)].
* *Cost-effectiveness analysis* (CEA) compares costs and outcomes expressed in a single dimension, such as fracture saved, BMD gained, or life-years gained.
* *Cost-utility analysis* (CUA) is considered as a specific case of CEA where the outcome measure is expressed in QALYs. The QALY estimator is an attractive outcome measurement in the field of osteoporosis because it offers the advantage of simultaneously capturing the benefits from a reduction in mortality and from a reduction in morbidity [[76](#_ENREF_76)]. In addition, this approach allows comparison across different health programs and diseases by using a generic unit of measure.

There are different categories of costs that may or may not be included in an economic evaluation. It is essential to specify and justify the perspective in which the analysis is undertaken. The most common perspectives used are those of healthcare payers and society. The societal perspective is the broadest, including direct and indirect medical costs, and is theoretically preferred [[70](#_ENREF_70)]. However, most local guidelines recommend the use of a healthcare payer perspective [[73](#_ENREF_73)].

The results of a CEA or CUA are usually expressed in terms of the incremental cost-effectiveness ratio (ICER), which is defined as the difference in terms of costs between two interventions divided by their difference in effectiveness. An ICER represents the additional cost of an intervention per effectiveness unit (for example, fracture saved or QALY gained) versus the comparator. The results can be presented graphically on the cost-effectiveness plane (**Figure 1**), where the difference in effectiveness between intervention **A** and comparator **O** is represented on the horizontal axis, and the difference in cost on the vertical axis [[77](#_ENREF_77)]. If **A** is located in quadrants II or IV, the choice is straightforward: in quadrant II, intervention **A** is more effective and less costly than comparator **O**, and said to be dominant; in quadrant IV, intervention **A** is less effective and more costly than **O**, and should be rejected. In quadrants I and III, there is no obvious decision; intervention **A** is either more effective and more costly than comparator **O** (quadrant I), or less effective and less costly (quadrant III). The choice will depend on the maximum amount the decision-maker is willing to pay (or accept) for a unit of effect (for example, a fracture prevented or a QALY). The slope of the line between intervention **A** and comparator **O** is the ICER. As shown in **Figure 1**, if intervention **A** falls below the ICER threshold, then it is deemed cost-effective.

In order to draw conclusions about an intervention’s cost-effectiveness, ICER should be compared with a cost-effectiveness threshold, above which the intervention would be deemed not cost-effective (because the additional cost for an additional unit of effect is too high) and below which it would be deemed cost-effective. The UK currently uses a threshold of £20 000 to £30 000 per QALY gained [[78](#_ENREF_78)], though most other countries define no generally accepted or recommended thresholds for cost-effectiveness. The objections to the specifications of a fixed cost-effectiveness threshold are numerous. First, any threshold for cost-effectiveness would be somewhat arbitrary and would be variable over time. A threshold would also vary between countries to reflect differences in resources. The WHO has suggested a cost-effectiveness threshold based on evaluating each disability-adjusted life-year (DALY) as three times the gross domestic product (GDP) per capita [[79](#_ENREF_79)]. On this basis, a willingness-to-pay of two times GDP per capita was used to define intervention thresholds in osteoporosis [[80](#_ENREF_80), [81](#_ENREF_81" \o "Borgstrom, 2006 #248)]. In addition, healthcare decision-making remains a multifactorial process and depends on many factors other than cost-effectiveness. As decisions are not solely based on ICER, it is probably not necessary to define a fixed threshold below which an intervention can be considered cost-effective. This should, however, not be used as an argument against the use of economic considerations in healthcare [[82](#_ENREF_82)]. In most countries, interventions with a low ICER have a higher probability of being adopted/accepted than those with a high value [[82](#_ENREF_82), [83](#_ENREF_83" \o "George, 2001 #252)]. Factors to considered alongside cost-effectiveness include burden of disease, uncertainty regarding cost-effectiveness, lack (or inadequacy) of alternative treatments, and overall financial implications for government [[84](#_ENREF_84)]; the seriousness of the disease and equity objectives are also important. Recently, the UK National Institute for Health and Clinical Excellence (NICE) introduced new criteria and increased the threshold for end of life treatments [[85](#_ENREF_85)].

Economic evaluation can be performed alongside randomized controlled trials [[86](#_ENREF_86)] or separately using decision-analytic modelling [[87](#_ENREF_87)]. The first approach estimates costs, effects, and utilities using individual patient data [[88](#_ENREF_88)], but suffers from a number of limitations that reduce its usefulness in informing decision-makers about the economic value of interventions. These include, for example, a failure to compare with all relevant options, a truncated time horizon, and a lack of relevance of the decision context [[89](#_ENREF_89)]. In addition, reliance on a single trial may ignore results from other clinical trials, meta-analyses, and observational studies [[87](#_ENREF_87)]. Decision-analytic models are therefore becoming a necessary feature for estimating the economic value of health interventions. This is especially true in osteoporosis since the prevention of an osteoporotic fracture (in particular of the hip or vertebra) has long-term consequences on costs and outcomes that may not be captured by trial data.

Healthcare modelling involves the application of mathematical techniques to summarize available information about healthcare processes and their implications [[90](#_ENREF_90)], usually with computer software. A model aims to represent the complexity of the process in a simple and comprehensible form [[91](#_ENREF_91)]. Modelling is useful to extrapolate beyond clinical trials, to combine multiple sources of evidence, to incorporate epidemiological, clinical, and economic data, and therefore to answer more relevant policy questions [[90](#_ENREF_90)]. In addition, modelling is also appropriate at the early stages of the development of a new technology to inform research priorities prior to initiation of clinical trials [[90](#_ENREF_90), [91](#_ENREF_91" \o "Buxton, 1997 #270)].

There may be some problems with using modelling in the economic evaluation of healthcare [[92](#_ENREF_92)]. Inappropriate use of modelling could lead to unreliable conclusions, as would be the case for combination of evidence from incompatible studies with a high degree of uncertainty, and oversimplification of some aspects of reality [[88](#_ENREF_88), [90](#_ENREF_90" \o "Brennan, 2000 #267)]. Manipulation could also be greater when modelling reflects commercial and government interests [[93](#_ENREF_93)]. An example is the discussion about the appraisal of NICE on the health economic assessment of interventions for the primary and secondary prevention of osteoporotic fractures in postmenopausal women in the UK [[94](#_ENREF_94)]. Some authors do not support the view of the NICE guideline and doubt the validity of the model and the appropriateness of the use of the model to inform its guidance [[95](#_ENREF_95)]. Interestingly, a recent study has shown that funding source (industry versus non-industry) did not seem to significantly affect the reporting of low or high ICERs for bisphosphonates [[96](#_ENREF_96)].

Models are only as good as their ability to represent the real world. In order for the results and conclusions of economic evaluation to be reliable and valid, it is crucial that the model and the data both represent the reality of the disease as accurately as possible. Guidelines have been developed to increase the quality and reliability of modelling [[73](#_ENREF_73), [97](#_ENREF_97" \o ", 2000 #274)]. These include the characterization of uncertainty using appropriate statistical approaches. There could be a substantial amount of uncertainty in the model parameters (and assumptions), and this should be explored using univariate and probabilistic sensitivity analyses. Univariate sensitivity analyses assess the impact of single parameters on the results (which can be represented as a tornado diagram [[98](#_ENREF_98)]), while probabilistic sensitivity analyses examine the effect of the joint uncertainty surrounding the model variables. Cost-effectiveness acceptability curves (CEAC) can then be constructed to show the probability that the intervention is cost-effective compared with the alternative, for a range of decision-maker’s willingness-to-pay thresholds. An example is shown in **Figure 2**. CEAC has been widely adopted to represent uncertainty in cost-effectiveness analyses [[99](#_ENREF_99)].

Economic evaluations conducted in the field of osteoporosis are usually based on so-called Markov state-transition models [[76](#_ENREF_76)]. Markov models are particularly appropriate when a decision problem involves a continuous risk over time, when the timing of events is important, and when events may happen more than once [[100](#_ENREF_100)], which is the case for osteoporosis. In a Markov model, a cohort of patients is followed over time along mutually exclusive health states (such as healthy, fracture states, and death). At the end of a cycle, patients can move to another health state according to transition probabilities. Values (typically cost and utilities) are assigned to each state and expected values are then obtained by summing costs and utilities across health states, weighted by the proportion of patients in each state, and then summing across cycles [[77](#_ENREF_77)]. To assess Markov models, either cohort or individual simulations can be carried out. A microsimulation model follows one individual at a time throughout the model. Due to the probabilistic structure of the model, there will be random variation in individual outcomes (called first-order uncertainty) [[101](#_ENREF_101)], which can be reduced by simulating a large number of patients. The major advantage of microsimulation is that a full patient history is recorded, which increases the reliability of the results and is currently largely compatible with existing state-of-the-art, evidence-based literature [[101](#_ENREF_101)]. The weakness of such models is that they require more sophisticated and detailed data than cohort-based models. This fact was invoked as a rationale for remaining with cohort modelling approaches in osteoporosis [[76](#_ENREF_76)].

**Economic evaluation in osteoporosis**

With limited healthcare resources, increasing awareness of osteoporosis, and new diagnostic tools and effective treatments, economic evaluation is increasingly widespread to help decision-makers allocate resources in osteoporosis. The number of published economic evaluations in osteoporosis has therefore markedly increased over recent years [[76](#_ENREF_76), [102-104](#_ENREF_102" \o "Muller, 2012 #286)]. They have mainly concerned treatment [[76](#_ENREF_76), [105](#_ENREF_105" \o "Fleurence, 2007 #296), [106](#_ENREF_106)] and screening strategies [[102](#_ENREF_102), [107](#_ENREF_107)]. Recent advances in the diagnosis and treatment of osteoporosis have provided new insights and challenges for economic evaluation that will be discussed below.

*Economic evaluation of new osteoporosis treatments*

As many countries now require economic evaluation as part of the submission file for drug reimbursement, novel drug treatments have been the subject of many economic analyses. Osteoporotic treatments are usually cost-effective in women aged over 60 or 70 years with low bone mass, especially those with prior fractures [[76](#_ENREF_76), [104](#_ENREF_104), [105](#_ENREF_105)]. In osteoporotic women aged over 80 years, drug therapies are generally reported to be cost-saving [[108](#_ENREF_108), [109](#_ENREF_109)], meaning that the cost of treating these patients is lower than the averted costs resulting from prevented fractures.

With the development of new products, the question of relevant comparators arises. Health economic evaluations should ideally compare a new intervention with the interventions it is likely to replace. In osteoporosis, there is a lack of head-to-head comparisons, which has led to a paucity of ICER comparisons between active treatments [[110](#_ENREF_110)]. No treatment (or calcium and vitamin D supplement) appears as the most widely used comparator [[76](#_ENREF_76)]. Cost-effectiveness analyses often replicate both arms of clinical trials (higher level of evidence) when active treatment is compared with placebo. It has also been argued that the current standard of care is no treatment, since osteoporosis is an undertreated disease and the majority of patients with osteoporosis do not receive any treatment [[110](#_ENREF_110)]. However, this is no longer true since there are many treatments available for osteoporosis that could be considered as standard care. Decision-makers are more interested in comparisons between active drugs to determine first-line options. As there is a lack of trial data directly comparing the effectiveness of different treatments, indirect comparison is required to assess cost-effectiveness between active comparators.

Cost-effectiveness analyses between active comparators have started to appear in the osteoporosis literature, for example, for denosumab [[98](#_ENREF_98), [111](#_ENREF_111)], strontium ranelate [[112](#_ENREF_112)] and zoledronic acid [[113](#_ENREF_113)]. Indirect comparisons of efficacy between drugs are less robust because of different baseline characteristics of the populations studied and overlapping confidence intervals for the effect of treatment [[114](#_ENREF_114)]. Such analyses should therefore be interpreted with great caution.

*Cost-effective intervention thresholds*

Recent developments in fracture risk assessment, such as the use of the FRAX algorithm, have led to new applications in health economics of osteoporosis. First, there is a growing body of literature on the interaction between FRAX and treatment efficacy suggesting that for some agents (for example, bazedoxifene, clodronate, denosumab), there is a significant interaction between fracture probability and efficacy [[115](#_ENREF_115)]. This has a significant impact on summary estimates of efficacy, and hence on cost-effectiveness.

Secondly, FRAX enables the estimation of risk based on a wider range of clinical risk factors and evaluation of treatment efficacy in populations at differing levels of risk [[116](#_ENREF_116)]. The cost-effectiveness of drug treatments can therefore be estimated in various types of patients with different combinations of clinical risk factors. FRAX can therefore help identify new high-risk populations (i.e. patients with different combinations of clinical risk factors) that could benefit from cost-effective treatment.

Finally, economic evaluations are also increasingly being used to determine cost-effective intervention thresholds in order to guide clinical guidelines. Thus, health economic evaluations have been conducted in several countries to determine at what levels of fracture risk treatment should be initiated [[80](#_ENREF_80), [81](#_ENREF_81" \o "Borgstrom, 2006 #248), [117](#_ENREF_117), [118](#_ENREF_118)]. In the UK, the intervention threshold at the age of 50 years corresponds to a 10-year probability of a major osteoporotic fracture of 7.5% [[117](#_ENREF_117)]. This increases progressively with age to 30% at the age of 80 years. In Switzerland, use of a fixed FRAX-based intervention threshold of 15% for both women and men would permit cost-effective treatment [[80](#_ENREF_80)]. In Belgium, a “translational approach” was used to define intervention thresholds by examining 10-year fracture probabilities equivalent to those currently accepted for reimbursement of treatment in Belgium (**Figure 3**) [[119](#_ENREF_119)]. This approach will, however, need to be supported by health economic analyses [[119](#_ENREF_119)]. Many country-dependent factors could have an impact on intervention thresholds, including fracture cost, intervention cost, and willingness-to-pay [[81](#_ENREF_81)]. Intervention thresholds should therefore be determined on a per-country basis.

*Economic value of improving adherence*

Consideration of new therapeutic options and behavioural interventions that improve medication adherence is currently leading to questions regarding their impact on clinical and economic outcomes. Several studies have assessed the effects of improvements in adherence on fracture outcomes [[120-123](#_ENREF_120)]. Other studies have estimated the potential economic value (in terms of cost per QALY gained) of interventions that improve medication adherence [[36](#_ENREF_36), [37](#_ENREF_37" \o "Landfeldt, 2011 #82), [64](#_ENREF_64), [124](#_ENREF_124)]. Currently, no studies have examined the cost-effectiveness of a specific adherence-enhancing intervention. The economic value of improving adherence was assessed using a variety of hypothetical interventions, which differ according to cost (e.g., marginal or one-time cost) and improvements in adherence (between 10% and 50%).

The results of these studies suggest that interventions that improve adherence are likely to confer cost-effective benefits [[36](#_ENREF_36), [37](#_ENREF_37" \o "Landfeldt, 2011 #82), [64](#_ENREF_64), [124](#_ENREF_124)]. Therefore, in the USA, a hypothetical intervention with a one-time cost of $250 that reduced discontinuation by 30% was reported to have an ICER of $29 571 per QALY gained [[124](#_ENREF_124)]. In studies conducted in Belgium [[36](#_ENREF_36)], Sweden [[37](#_ENREF_37)], and Ireland [[64](#_ENREF_64)], it has been estimated that an intervention that improves adherence by 10% is cost-effective at a maximum yearly cost of between €45 and €70 (**Figure 4**). For a hypothetical intervention that improves adherence by 50%, it is cost-effective to spend between €140 and €239 per year. The economic value of improving adherence could be situation-specific and improve with the increasing baseline risk for fractures [[64](#_ENREF_64), [124](#_ENREF_124" \o "Patrick, 2011 #339)].

This work has required methods of incorporating medication adherence into the models. As medication non-adherence affects both costs and outcomes, it could have a substantial impact on the cost-effectiveness of management strategies in osteoporosis and should be incorporated in pharmacoeconomic analyses [[64](#_ENREF_64), [122](#_ENREF_122" \o "Hiligsmann, 2010 #335), [125](#_ENREF_125)]. In particular, when comparing drugs with different adherence profiles, the lack of inclusion of these concepts could bias the results and lead to suboptimal allocation of resources [[126](#_ENREF_126)]. Integrating medication adherence into economic analyses in osteoporosis is a complex and difficult task, and has been extensively discussed elsewhere [[74](#_ENREF_74), [126](#_ENREF_126" \o "Hiligsmann, 2012 #318)].

**Discussion**

An increasing number of epidemiological and economic studies have revealed the immense burden of osteoporotic fractures, and this is expected to increase further in the future. Information from these studies will help establish priorities between interventions and diseases and guide research priorities. Furthermore, economic analyses have suggested that recent advances in the prevention and treatment of osteoporosis, including novel treatments, fracture risk assessment, and improved medication adherence, are an appropriate and efficient way of allocating healthcare resources. Such analyses may also contribute to a more efficient healthcare system.

HTA is a rapidly evolving discipline. As more countries use HTA to inform healthcare decisions, the harmonization of HTA between jurisdictions has been discussed in order to avoid duplication of effort [[127](#_ENREF_127)]. Clinical data for new technologies usually apply across countries, but cost-effectiveness (and therefore appraisals of technologies for reimbursement) should be evaluated at a national level because differences in the incidence of the disease, the availability of health resources, clinical practice patterns, and relative prices may impact on cost-effectiveness [[128](#_ENREF_128)]. The development of key principles [[129](#_ENREF_129)] and good practice, as well as international collaboration between experts, could facilitate a common process for the conduct of HTA for resource-allocation decisions.

There are currently major developments in the methods for economic evaluation in osteoporosis:

* Incorporation of medication adherence into pharmacoeconomic analyses in osteoporosis [[74](#_ENREF_74), [126](#_ENREF_126" \o "Hiligsmann, 2012 #318)].
* Use of FRAX in health economics of osteoporosis [[116](#_ENREF_116)].
* Use of microsimulation models, which are beginning to supplant cohort models in HTA [[130](#_ENREF_130)].
* In the absence of randomized controlled trials directly comparing active comparators, use of indirect treatment comparisons and network meta-analysis may provide useful evidence for selecting the best option [[131](#_ENREF_131)].
* Characterization of uncertainty.

Alternative approaches to the assessment of QALY have also been developed, including discrete-choice experiment (DCE) [[132](#_ENREF_132), [133](#_ENREF_133" \o "de Bekker-Grob, 2008 #407)] and contingent valuation. DCEs have been increasingly used to elicit collective preferences of subgroups of patients in healthcare [[134](#_ENREF_134)]. DCE is an attribute-based survey approach for measuring value, in which patient preference is determined by the levels of different attributes [[135](#_ENREF_135)]. DCEs help determine important attributes and provide input on what patients with a particular disease prefer and/or are willing to pay.

Despite the growth of HTA over the past decades, its overall impact on policy-making may be limited [[14](#_ENREF_14)]. The role of science is however to inform, not to dictate policy decisions. Humphreys and Piot recently argued that scientific evidence alone is not a sufficient basis for health policy and that other factors (such as democratic and human rights considerations) should be taken into consideration in health policy [[136](#_ENREF_136)].

In summary, HTA helps decision-makers efficiently allocate healthcare resources. In the field of osteoporosis, HTA reports have revealed a considerable burden of fracture and the economic value of the prevention of fracture and the treatment of osteoporosis.

**Disclosure statement of potential conflicts of interest**

Jean-Jacques BODY has received speaker and consultant fees from Amgen and Novartis, and research support from Amgen, Daïïchi-Sankyo, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Nycomed, Servier, SMB.

Pierre BERGMANN has received speaker fees from Servier and Roche.

Steven BOONEN has received consulting fees and/or research support from: Amgen, Merck, Novartis and Servier

Olivier Bruyère has received grants or has been reimbursed for attending meetings from GlaxoSmithKline, IBSA, MSD, Novartis, Rottapharm, Servier, Theramex and Wyeth

Juliet Compston has received grant support from GlaxoSmithKline and Nycomed, advisory fees and/or speaking fees from Alliance for Better Bone Health, Amgen, Gilead, GlaxoSmithKline, Medtronic, MSD, Novartis, Nycomed, Servier, Warner-Chilcott.

Cyrus Cooper has received consulting fees and paid advisory boards for Alliance for Better Bone Health, GlaxoSmithKline, Roche, Merck Sharp and Dohme, Lilly, Amgen, Wyeth, Novartis, Servier, and Nycomed.

Jean-Pierre DEVOGELAER has no conflict of interest

Bruno Flamion has no conflict of interest

Stephan GOEMAERE has received speakers fees and/or research support from Amgen, Daichi Sankyo, Eli Lilly, Glaxo Smith Kline, Merck Sharp & Dohme, Novartis, Nycomed, Warner Chillcott, Sanofi-Aventis, Servier, Roche.

Mickael Hiligsmann has received research grants from Amgen, Novartis, Pfizer, Servier, SMB, and consulting fees from Servier and SMB.

Jean-Marc KAUFMAN has received Consulting fees, paid advisory boards, lecture fees and/or grant support from Amgen, Eli Lilly, Glaxo Smith Kline, Merck, Novartis, Procter & Gamble, Roche, Sanofi Aventis, Servier, Warner Chilcott.

John A. Kanis has received consulting fees, advisory board fees, lecture fees, and/or grant support from the majority of companies concerned with skeletal metabolism.

Serge ROZENBERG has received speakers or and consultant fees from Amgen, Merck Sharp & Dohme and Pfizer.

Jean-Yves REGINSTER on behalf of the Department of Public Health, Epidemiology and Health Economics of the University of Liège, Liège, Belgium.

Consulting fees or paid advisory boards: Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS, Theramex, UCB.

Lecture fees when speaking at the invitation of a commercial sponsor: Merck Sharp and Dohme, Lilly, Rottapharm, IBSA, Genevrier, Novartis, Servier, Roche, GlaxoSmithKline, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Theramex, Nycomed, Novo-Nordisk.

Grant Support from Industry: Bristol Myers Squibb, Merck Sharp & Dohme, Rottapharm, Teva, Lilly, Novartis, Roche, GlaxoSmithKline, Amgen, Servier.

**References**

1. Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C. (2009) Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 20:1633-50.

2. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B. (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108-12.

3. Hiligsmann M, Bruyere O, Ethgen O, Gathon HJ, Reginster JY. (2008) Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. Bone 43:991-4.

4. Kanis JA, Johnell O, Oden A, et al. (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669-74.

5. Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C. (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. doi 10.1007/s00198-012-1964-3

6. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK. (2002) International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 17:1237-44.

7. Harvey N, Dennison E, Cooper C. (2010) Osteoporosis: impact on health and economics. Nat Rev Rheumatol 6:99-105.

8. Ström O, Borgström F, Kanis J, et al. (2011) Osteoporosis: Burden, health care provision and opportunities in the European Union. Archives of Osteoporosis 6:59-155.

9. Kanis JA, McCloskey EV, Johansson H, et al. (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23-57.

10. International Network of Agencies of Health Technology Assessment INAHTA glossary. <http://www.inahta.org/HTA/Glossary/#_Health_Technology_Assessment>. Accessed 1 April 2012.

11. Jonsson E, Banta D. (1999) Management of health technologies: an international view. Bmj 319:1293-U42.

12. Banta D, Jonsson E. (2009) History of HTA: Introduction. Int J Technol Assess Health Care 25 Suppl 1:1-6.

13. Martelli F, La Torre G, Di Ghionno E, et al. (2007) Health technology assessment agencies: an international overview of organizational aspects. Int J Technol Assess Health Care 23:414-24.

14. Oliver A, Mossialos E, Robinson R. (2004) Health technology assessment and its influence on health-care priority setting. Int J Technol Assess Health Care 20:1-10.

15. Banta D, Oortwijn W. (2000) Health technology assessment and health care in the European Union. Int J Technol Assess Health Care 16:626-35.

16. Goodman C. HTA 101. Introduction to Health Technology Assessment. <http://www.nlm.nih.gov/nichsr/hta101/hta101.pdf>. Accessed 1 April 2012.

17. Melton LJ, 3rd, Chrischilles EA, Cooper C, Lane AW, Riggs BL. (1992) Perspective. How many women have osteoporosis? J Bone Miner Res 7:1005-10.

18. van Staa TP, Dennison EM, Leufkens HG, Cooper C. (2001) Epidemiology of fractures in England and Wales. Bone 29:517-22.

19. Dhanwal DK, Cooper C, Dennison EM. (2010) Geographic variation in osteoporotic hip fracture incidence: the growing importance of asian influences in coming decades. J Osteoporos 2010:757102.

20. Johnell O, Borgstrom F, Jonsson B, Kanis J. (2007) Latitude, socioeconomic prosperity, mobile phones and hip fracture risk. Osteoporos Int 18:333-7.

21. Elffors I, Allander E, Kanis JA, et al. (1994) The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int 4:253-63.

22. Roy DK, Pye SR, Lunt M, et al. (2002) Falls explain between-center differences in the incidence of limb fracture across Europe. Bone 31:712-7.

23. Langley J, Samaranayaka A, Davie G, Campbell AJ. (2011) Age, cohort and period effects on hip fracture incidence: analysis and predictions from New Zealand data 1974-2007. Osteoporos Int 22:105-11.

24. Martyn CN, Cooper C. (1999) Prediction of burden of hip fracture. Lancet 353:769-70.

25. Javaid MK, Crozier SR, Harvey NC, et al. (2006) Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet 367:36-43.

26. Cooper C, Campion G, Melton LJ, 3rd. (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285-9.

27. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. (2009) Incidence and mortality of hip fractures in the United States. Jama 302:1573-9.

28. Cooper C, Cole ZA, Holroyd CR, et al. (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277-88.

29. Melton LJ, 3rd, Kearns AE, Atkinson EJ, et al. (2009) Secular trends in hip fracture incidence and recurrence. Osteoporos Int 20:687-94.

30. Hiligsmann M, Bruyere O, Roberfroid D, et al. (2012) Trends in hip fracture incidence and in the prescription of anti-osteoporosis medications during same time period in Belgium (2000-2007). Arthritis Care Res (Hoboken) 64:744-50

31. Reginster JY, Gillet P, Gosset C. (2001) Secular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy. Bull World Health Organ 79:942-6.

32. Abrahamsen B, Vestergaard P. (2010) Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006. Osteoporos Int 21:373-80.

33. Melton LJ, 3rd, Kanis JA, Johnell O. (2005) Potential impact of osteoporosis treatment on hip fracture trends. J Bone Miner Res 20:895-7.

34. Rachner TD, Khosla S, Hofbauer LC. (2011) Osteoporosis: now and the future. Lancet 377:1276-87.

35. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385-97.

36. Hiligsmann M, Rabenda V, Bruyere O, Reginster JY. (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96:170-7.

37. Landfeldt E, Lundkvist J, Strom O. (2011) The societal burden of poor persistence to treatment of osteoporosis in Sweden. Bone 48:380-8.

38. Silverman SL, Christiansen C, Genant HK, et al. (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923-34.

39. Cummings SR, San Martin J, McClung MR, et al. (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-65.

40. Reginster JY, Adami S, Lakatos P, et al. (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65:654-61.

41. Reginster JY, Seeman E, De Vernejoul MC, et al. (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816-22.

42. Black DM, Delmas PD, Eastell R, et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-22.

43. Cooper C, Reginster JY, Cortet B, et al. (2012) Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr Med Res Opin 28:475-91.

44. Mazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A. (2012) New understanding and treatments for osteoporosis. Endocrine 41:58-69.

45. Devogelaer JP, Goemaere S, Boonen S, et al. (2006) Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 17:8-19.

46. Body JJ, Bergmann P, Boonen S, et al. (2010) Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 21:1657-80.

47. Marshall D, Johnell O, Wedel H. (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Bmj 312:1254-9.

48. Kanis JA, Oden A, Johnell O, et al. (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033-46.

49. Ensrud KE, Lui LY, Taylor BC, et al. (2009) A comparison of prediction models for fractures in older women: is more better? Arch Intern Med 169:2087-94.

50. Hippisley-Cox J, Coupland C. (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. Bmj 339:b4229.

51. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. (2007) Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 18:1109-17.

52. Kanis JA, Oden A, Johansson H, McCloskey E. (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23:423-31.

53. Kanis JA, Hans D, Cooper C, et al. (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395-411.

54. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. (2011) Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 22:839-47.

55. Kanis JA, Johansson H, Oden A, McCloskey EV. (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809-16.

56. Gehlbach S, Saag KG, Adachi JD, et al. (2012) Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women. J Bone Miner Res 27:645-53

57. Black DM, Arden NK, Palermo L, Pearson J, Cummings SR. (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14:821-8.

58. Kayan K, Johansson H, Oden A, et al. (2009) Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate. Osteoporos Int 20:2055-61.

59. Huybrechts KF, Ishak KJ, Caro JJ. (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-8.

60. Rabenda V, Mertens R, Fabri V, et al. (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811-8.

61. Weycker D, Macarios D, Edelsberg J, Oster G. (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645-52.

62. Rabenda V, Reginster JY. (2010) Overcoming problems with adherence to osteoporosis medication. Expert Rev Pharmacoecon Outcomes Res 10:677-89.

63. Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14:571-81.

64. Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY. (2012) The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health doi:10.1016/j.jval.2012.02.001

65. Gleeson T, Iversen MD, Avorn J, et al. (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20:2127-34.

66. Hiligsmann M, Salas M, Hughes DA, et al. (2011) Most Effective Patient Compliance Interventions with Osteoporosis Medications. Value Health. Abstract ISPOR 16th Annual International Meeting, Philadelphia.

67. Freemantle N, Satram-Hoang S, Tang ET, et al. (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317-26.

68. Montori VM, Shah ND, Pencille LJ, et al. (2011) Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med 124:549-56.

69. Nielsen D, Ryg J, Nielsen W, Knold B, Nissen N, Brixen K. (2010) Patient education in groups increases knowledge of osteoporosis and adherence to treatment: a two-year randomized controlled trial. Patient Educ Couns 81:155-60.

70. Drummond M, Sculpher M, O'Brien B, Stoddart G, Torrance G. (2007) Methods for the economic evaluation of health care programmes, 3th edition. New-York: Oxford University Press.

71. Taylor RS, Drummond MF, Salkeld G, Sullivan SD. (2004) Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. Bmj 329:972-5.

72. Drummond M, Jonsson B, Rutten F. (1997) The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 40:199-215.

73. Cleemput I, van Wilder P, Huybrechts M, Vrijens F. (2009) Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 12:441-49.

74. Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R. (2011) Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 22:2565-73.

75. Palmer S, Byford S, Raftery J. (1999) Economics notes: types of economic evaluation. Bmj 318:1349.

76. Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B. (2007) Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model. Osteoporos Int 18:9-23.

77. Briggs A, Claxton K, Sculpher M. (2007) Decision modelling for health economic evaluation, 2nd edition. New-York: Oxford University Pres.

78. Raftery J. (2001) NICE: faster access to modern treatments? Analysis of guidance on health technologies. Bmj 323:1300-3.

79. World Health Organization (2011) Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission onMacroeconomics and Health. <http://whqlibdoc.who.int/publications/2001/924154550x.pdf>. Accessed 10 April 2012.

80. Lippuner K, Johansson H, Borgstrom F, Kanis JA, Rizzoli R. (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX(R) in Switzerland. Osteoporos Int doi: 10.1007/s00198-011-1869-6

81. Borgstrom F, Johnell O, Kanis JA, Jonsson B, Rehnberg C. (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17:1459-71.

82. Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. (2008) Threshold values for cost-effectiveness in health care. Health Technology Assessment (HTA). Bruxelles: Belgian Health Care Knowledge Centre (KCE). KCE Reports 100B (D/2008/10.273/95).

83. George B, Harris A, Mitchell A. (2001) Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 19:1103-9.

84. Devlin N, Parkin D. (2004) Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 13:437-52.

85. National institute for Health and Clinical Excellence (2012). Appraising life-extending, end of life treatments.

<http://www.nice.org.uk/media/88A/F2/SupplementaryAdviceTACEoL.pdf>. Accessed 10 April 2012.

86. Petrou S, Gray A. (2011) Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. Bmj 342:d1548.

87. Petrou S, Gray A. (2011) Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. Bmj 342:d1766.

88. O'Brien B. (1996) Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials? Med Care 34:DS99-108.

89. Sculpher MJ, Claxton K, Drummond M, McCabe C. (2006) Whither trial-based economic evaluation for health care decision making? Health Econ 15:677-87.

90. Brennan A, Akehurst R. (2000) Modelling in health economic evaluation. What is its place? What is its value? Pharmacoeconomics 17:445-59.

91. Buxton MJ, Drummond MF, Van Hout BA, et al. (1997) Modelling in economic evaluation: an unavoidable fact of life. Health Econ 6:217-27.

92. Sheldon TA. (1996) Problems of using modelling in the economic evaluation of health care. Health Econ 5:1-11.

93. Kassirer JP, Angell M. (1994) The journal's policy on cost-effectiveness analyses. N Engl J Med 331:669-70.

94. National Institute for Health and Clinical Excellence (2010). Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women.

95. Kanis J, McCloskey E, Jonsson B, Cooper A, Ström O, Borgström F. (2012) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Archives of Osteoporosis 5:19-48.

96. Fleurence RL, Spackman DE, Hollenbeak C. (2010) Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis. Pharmacoeconomics 28:295-306.

97. (2000) Decision analytic modelling in the economic evaluation of health technologies. A consensus statement. Consensus Conference on Guidelines on Economic Modelling in Health Technology Assessment. Pharmacoeconomics 17:443-4.

98. Hiligsmann M, Reginster JY. (2011) Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 29:895-911.

99. Fenwick E, O'Brien BJ, Briggs A. (2004) Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. Health Econ 13:405-15.

100. Sonnenberg FA, Beck JR. (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322-38.

101. Hiligsmann M, Ethgen O, Bruyere O, Richy F, Gathon HJ, Reginster JY. (2009) Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12:687-96.

102. Muller D, Pulm J, Gandjour A. (2012) Cost-effectiveness of different strategies for selecting and treating individuals at increased risk of osteoporosis or osteopenia: a systematic review. Value Health 15:284-98.

103. Zethraeus N, Ben Sedrine W, Caulin F, et al. (2002) Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 13:841-57.

104. Hiligsmann M, Reginster JY. (2012) Health economics in osteoporosis. Temas (topics) de osteoporosis y otras enfermedades oseas. p. 337-58.

105. Fleurence RL, Iglesias CP, Johnson JM. (2007) The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics 25:913-33.

106. Fleurence RL, Iglesias CP, Torgerson DJ. (2006) Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporos Int 17:29-40.

107. Schousboe JT. (2008) Cost effectiveness of screen-and-treat strategies for low bone mineral density: how do we screen, who do we screen and who do we treat? Appl Health Econ Health Policy 6:1-18.

108. Hiligsmann M, Bruyere O, Reginster JY. (2010) Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int 21:157-65.

109. Hiligsmann M, Reginster JY. (2010) Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 47:34-40.

110. Borgstrom F, Kanis JA. (2008) Health economics of osteoporosis. Best Pract Res Clin Endocrinol Metab 22:885-900.

111. Jonsson B, Strom O, Eisman JA, et al. (2011) Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22:967-82.

112. Hiligsmann M, Bruyere O, Reginster JY. (2010) Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone 46:440-6.

113. Akehurst R, Brereton N, Ariely R, et al. (2011) The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands. J Med Econ 14:53-64.

114. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-8.

115. Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD. (2012) FRAX((R)) with and without bone mineral density. Calcif Tissue Int 90:1-13.

116. Strom O, Borgstrom F, Kleman M, et al. (2010) FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 47:430-7.

117. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. (2008) Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int 19:1395-408.

118. Tosteson AN, Melton LJ, 3rd, Dawson-Hughes B, et al. (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437-47.

119. Johansson H, Kanis JA, McCloskey EV, et al. (2011) A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453-61.

120. Danese MD, Badamgarav E, Bauer DC. (2009) Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. J Bone Miner Res 24:1819-26.

121. Cotte FE, Cortet B, Lafuma A, et al. (2008) A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France. Joint Bone Spine 75:201-8.

122. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY. (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86:202-10.

123. Rietbrock S, Olson M, van Staa TP. (2009) The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. Qjm 102:35-42.

124. Patrick AR, Schousboe JT, Losina E, Solomon DH. (2011) The economics of improving medication adherence in osteoporosis: validation and application of a simulation model. J Clin Endocrinol Metab 96:2762-70.

125. Strom O, Borgstrom F, Kanis JA, Jonsson B. (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20:23-34.

126. Hiligsmann M, Boonen A, Rabenda V, Reginster JY. (2012) The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 12:159-66.

127. Hutton J, Trueman P, Facey K. (2008) Harmonization of evidence requirements for health technology assessment in reimbursement decision making. Int J Technol Assess Health Care 24:511-7.

128. Drummond M, Barbieri M, Cook J, et al. (2009) Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 12:409-18.

129. Drummond MF, Schwartz JS, Jonsson B, et al. (2008) Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 24:244-58; discussion 362-8.

130. Weinstein MC. (2006) Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 24:1043-53.

131. Hoaglin DC, Hawkins N, Jansen JP, et al. (2011) Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 14:429-37.

132. Darba J, Restovic G, Kaskens L, et al. (2011) Patient preferences for osteoporosis in Spain: a discrete choice experiment. Osteoporos Int 22:1947-54.

133. de Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Pols HA, Koes BW, Steyerberg EW. (2008) Patients' preferences for osteoporosis drug treatment: a discrete choice experiment. Osteoporos Int 19:1029-37.

134. Lancsar E, Louviere J. (2008) Conducting discrete choice experiments to inform healthcare decision making: a user's guide. Pharmacoeconomics 26:661-77.

135. Ryan M. (2004) Discrete choice experiments in health care. Bmj 328:360-1.

136. Humphreys K, Piot P. (2012) Scientific evidence alone is not sufficient basis for health policy. Bmj 344:e1316.

**Figure legends**

**Figure 1.** Cost-effectiveness plane.

The difference in QALYs between intervention **A** and comparator **O** is represented on the horizontal axis, and the difference in cost on the vertical axis. The slope of the line between intervention **A** and comparator **O** is the incremental cost-effectiveness ratio (ICER). If **A** is located in quadrants II or IV, intervention **A** is dominant (more effective and less costly than comparator **O)**, in quadrant IV, intervention **A** is less effective and more costly than **O**. In quadrants I intervention **A** is more effective but more costly and in III less effective and less costly. The choice will depend on the cost-effectiveness threshold that represents the maximum amount the decision-maker is willing to pay for a unit of effectiveness. Interventions that fall below the cost-effective threshold would be deemed cost-effective.

**Figure 2.** Example of a cost-effectiveness acceptability curve.

This graph shows the probability of an osteoporotic treatment being cost-effective compared with no treatment in patients aged 70 years with prevalent vertebral fractures, as a function of the decision-maker's willingness-to-pay per one QALY [[108](#_ENREF_108)].

The curve was estimated from probabilistic sensitivity analyses where most parameters (such as therapeutic effect, fracture risk, cost, and disutility) were assigned a probability distribution (e.g. normal or uniform distribution) and values from each distribution were randomly selected during a predefined number of simulations.

**Figure 3.** Intervention thresholds in Belgium [[119](#_ENREF_119)] (copyright permission from springer).

**Figure 4.** Maximum yearly cost (in €) for an adherence-enhancing intervention to be considered cost-effective. Data from [[36](#_ENREF_36), [37](#_ENREF_37), [64](#_ENREF_64)].

For Sweden, improvement in medication adherence at 25% should be read at 30%. In Ireland, a longer refill gap period (9-weeks) was selected to define persistence resulting in higher base-case adherence levels.

Effect difference

Cost difference

différentiel

III

IV

II

I

**O**

Threshold ratio

